Oka Satoko, Muroi Kazuo, Matsuyama Tomohiro, Sato Kazuya, Ueda Masuzu, Toshima Masaki, Suzuki Takahiro, Ozaki Katsutoshi, Mori Masaki, Takubo Takayuki, Nagai Tadashi, Hanafusa Toshiaki, Ozawa Keiya
Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Hematology. 2009 Jun;14(3):133-8. doi: 10.1179/102453309X402269.
Determination of the percentage of myeloblasts in bone marrow is important for the evaluation of acute myeloblastic leukemia (AML) and related disorders. Using flow cytometry with a CD45-blast gate (FCM/CD45), 226 bone marrow aspiration samples serially collected from 71 patients with de novo AML were analyzed. Bone marrow smears were evaluated independently by pathologists who did not know the corresponding flow cytometric data in advance. Patients received remission induction followed by consolidation. The CD33+ cell percentages evaluated by FCM/CD45 were strongly correlated to the myeloblast percentages determined by microscopic examination (r=0.8360, p<0.001). When only samples containing leukemic cells demonstrated by chromosomal or fluorescence in situ hybridization (FISH) analysis after induction were evaluated, positive correlations were found between CD33+ cell percentages determined by FCM/CD45 and myeloblast percentages determined by morphology (r=0.672, p<0.001). The identification of CD33+ cells by FCM/CD45 is useful for the evaluation of bone marrow myeloblasts in AML.
测定骨髓中原始粒细胞的百分比对于评估急性髓细胞白血病（AML）及相关疾病很重要。使用带有CD45原始细胞设门的流式细胞术（FCM/CD45），对71例初发AML患者连续采集的226份骨髓穿刺样本进行了分析。骨髓涂片由事先不知道相应流式细胞术数据的病理学家独立评估。患者接受缓解诱导治疗，随后进行巩固治疗。通过FCM/CD45评估的CD33+细胞百分比与显微镜检查确定的原始粒细胞百分比密切相关（r=0.8360，p<0.001）。当仅评估诱导后经染色体或荧光原位杂交（FISH）分析显示含有白血病细胞的样本时，通过FCM/CD45确定的CD33+细胞百分比与形态学确定的原始粒细胞百分比之间存在正相关（r=0.672，p<0.001）。通过FCM/CD45鉴定CD33+细胞有助于评估AML患者骨髓中的原始粒细胞。
